美国 · SEC FORM 4
Erasca, Inc.
ERAS · Nasdaq · CIK 0001761918 · Healthcare · Biotechnology
内部人信号
0 qualifying P purchase groups
当前 180 天评分窗口
0 同一窗口内观察到的 Form 4 交易行
0 sales · 0 期权、代扣税、授予、赠与或其他交易行
为什么没有活跃信号？
评分构成
活跃窗口内没有合资格买入，因此不计算分数。缺失的输入不会被当作零分或看空信号。
为什么没有分数？
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示，不会形成负分。
卖出和其他 Form 4 活动会单独显示，不会形成负面买入信号。没有买入不会被评分为看空。
内部人活动时间轴
当前 180 天窗口内没有 Form 4 交易事件。
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后，这些模块才会启用。
信号历史
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2024-05-21 · Casdin Alexander W..
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 35,338,107
- 上期报告
- 33,036,139
- 日均成交量
- 5,143,537
- 回补天数
- 6.9
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2024-05-21 | Casdin Alexander W. | 买入 (P) | Common Stock | 80,000 | USD 2.27 | USD 181,600 | SEC 申报 ↗ |
| 2023-12-06 | Start Valerie Denise Harding | 买入 (P) | Common Stock | 10,000 | USD 1.85 | USD 18,500 | SEC 申报 ↗ |
| 2023-12-06 | Lim Jonathan E | 买入 (P) | Common Stock | 278,150 | USD 1.72 | USD 478,418 | SEC 申报 ↗ |
| 2023-12-05 | Lim Jonathan E | 买入 (P) | Common Stock | 721,850 | USD 1.69 | USD 1,219,926 | SEC 申报 ↗ |
| 2023-12-04 | Casdin Alexander W. | 买入 (P) | Common Stock | 30,000 | USD 1.66 | USD 49,800 | SEC 申报 ↗ |
| 2023-10-05 | Lim Jonathan E | 买入 (P) | Common Stock | 1,000,000 | USD 2.03 | USD 2,030,000 | SEC 申报 ↗ |
| 2023-06-08 | Lim Jonathan E | 买入 (P) | Common Stock | 100,000 | USD 2.75 | USD 275,000 | SEC 申报 ↗ |
| 2023-04-10 | Casdin Alexander W. | 买入 (P) | Common Stock | 20,000 | USD 2.76 | USD 55,200 | SEC 申报 ↗ |
| 2023-03-28 | Lim Jonathan E | 买入 (P) | Common Stock | 100,000 | USD 2.84 | USD 284,000 | SEC 申报 ↗ |
| 2023-01-10 | Lim Jonathan E | 买入 (P) | Common Stock | 60,000 | USD 3.86 | USD 231,600 | SEC 申报 ↗ |
| 2022-12-21 | Start Valerie Denise Harding | 买入 (P) | Common Stock | 10,000 | USD 4.64 | USD 46,400 | SEC 申报 ↗ |
| 2022-12-21 | Bristol James Arthur | 买入 (P) | Common Stock | 20,000 | USD 4.14 | USD 82,800 | SEC 申报 ↗ |
| 2022-12-15 | Casdin Alexander W. | 买入 (P) | Common Stock | 20,000 | USD 4.87 | USD 97,400 | SEC 申报 ↗ |
| 2022-12-14 | Lim Jonathan E | 买入 (P) | Common Stock | 40,000 | USD 4.99 | USD 199,600 | SEC 申报 ↗ |
| 2022-12-13 | Chen Bihua; Cormorant Asset Management, LP; Cormorant Global Healthcare Master Fund, LP; Cormorant Private Healthcare Fund II, LP | 买入 (P) | Common Stock | 307,692 | USD 6.50 | USD 1,999,998 | SEC 申报 ↗ |
Form 4 申报证据
8 transaction lines in the latest 365-day window; 55 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-04-01 | Garner Ebun | 卖出 (S) | Common Stock | 80,000 | USD 16.40 | USD 1,312,000 | SEC 申报 ↗ |
| 2026-04-01 | Garner Ebun | 期权行权／转换 (M) | Common Stock | 80,000 | USD 1.70 | USD 136,000 | SEC 申报 ↗ |
| 2026-03-04 | Morris Shannon | 卖出 (S) | Common Stock | 20,000 | USD 15.04 | USD 300,800 | SEC 申报 ↗ |
展开近期 Form 4 证据 (8 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-04-01 | Garner Ebun | 卖出 (S) | Common Stock | 80,000 | USD 16.40 | USD 1,312,000 | SEC 申报 ↗ |
| 2026-04-01 | Garner Ebun | 期权行权／转换 (M) | Common Stock | 80,000 | USD 1.70 | USD 136,000 | SEC 申报 ↗ |
| 2026-03-04 | Morris Shannon | 卖出 (S) | Common Stock | 20,000 | USD 15.04 | USD 300,800 | SEC 申报 ↗ |
| 2026-03-04 | Morris Shannon | 期权行权／转换 (M) | Common Stock | 20,000 | USD 1.70 | USD 34,000 | SEC 申报 ↗ |
| 2026-01-07 | Garner Ebun | 卖出 (S) | Common Stock | 120,000 | USD 5.59 | USD 670,800 | SEC 申报 ↗ |
| 2026-01-07 | Garner Ebun | 期权行权／转换 (M) | Common Stock | 120,000 | USD 1.70 | USD 204,000 | SEC 申报 ↗ |
| 2025-12-15 | Chacko David M. | J (J) | Common Stock | 17,793 | USD 1.19 | USD 21,174 | SEC 申报 ↗ |
| 2025-12-15 | Garner Ebun | 奖励／授予 (A) | Common Stock | 3,902 | USD 1.19 | USD 4,643 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | ERAS |
| CIK | 0001761918 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 55 transaction lines from 2021-07-20 to 2026-04-01 22 P purchase lines · 4 S sale lines · 29 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.